Taken together, their results provide the evidence that the [131I]ICF01012 and MEKi combination can be beneficial for the treatment of the advanced pigmented BRAF-mutant melanoma and that [131I]ICF01012 alone is promising for the treatment of NRAS-mutant melanoma. Here, BRAF is linked to melanoma.